肝病与胃肠道疾病杂志
开放获取

抽象的

脂肪肝：肌肉减少症的诊断和治疗回顾

胡安·曼努埃尔·瓜迪亚-巴埃纳、卡门·卡斯特拉诺斯·卢赫、比阿特丽斯·费尔南德斯·梅迪纳、胡安·包蒂斯塔·莫罗·埃尔南德斯、玛丽亚姆·西达希·塞拉诺

Despite being a prevalent disease, Steatotic Liver Disease (SLD) is not as well recognized by clinicians as other metabolic diseases. The high prevalence of SLD and the associated high morbidity and mortality require an early diagnosis of the disease because of its potential evolution to malignancy.

Sarcopenia is present in 22%-62% of patients with cirrhosis. Given the overlapping pathophysiology between SLD and sarcopenia, it is difficult to determine whether sarcopenia is a genuine pathogenic factor in the development of SLD or a complication of it. Diagnostic methods have been developed to assess muscle mass in patients with SLD, but neither are they standardized nor is there a definite pharmacological therapy for treating sarcopenia or cachexia at the clinical level.

Nutritional assessment should be a fundamental part of the initial approach to the patient with SLD and their subsequent follow-up.